Globally, over 40 million people live with HIV, facing lifelong treatment with antiretroviral therapy (ART). While advances have transformed HIV from a fatal disease into a manageable condition, a definitive cure has remained elusive—until now. Recent studies suggest that achieving a “functional” cure, where the virus remains suppressed without continuous medication, might soon be possible.

In 2025, two independent clinical trials demonstrated promising results. Using engineered antibody infusions, some participants maintained undetectable viral loads long after stopping treatment. These findings could revolutionize HIV management by reducing dependence on daily medication, improving quality of life, and lowering healthcare costs.

One notable study—the FRESH trial—led by virologist Thumbi Ndung’u in South Africa, observed that four out of 20 participants remained free of detectable HIV for a median of 1.5 years without ART. Meanwhile, the RIO trial, conducted in the UK and Denmark under researcher Sarah Fidler, found that six of 34 patients maintained viral suppression for at least two years.

Experts emphasize cautious optimism. According to infectious disease specialist Dr. Jane Smith, “These results are a significant step toward functional cures, but more research is needed to understand long-term effects.” Such breakthroughs raise hope for millions, making long-term remission a tangible goal in the near future.

David Nield

Dave is a freelance tech journalist with over 20 years covering gadgets, apps, and the web. From Stockport, England, he covers news, features, and reviews for TechRadar, focusing on phones, tablets, and wearables. He ensures top weekend breaking news and has bylines at Gizmodo, T3, PopSci, and others. He edited PC Explorer and The Hardware Handbook for years. Read me on x.com or linkedin.